A population-based observational cohort study compares the three third-generation aromatase inhibitors—letrozole, anastrozole, and exemestane—for hormone receptor-positive breast cancer and reports disease free survival at 5 years with perfect compliance is slightly less with exemestane (88%) than the others (90%), as was compliance: 39% discontinuation with exemestane versus 35% with the others. | Dumas, JAMA Netw Open 2025
